Treatment of liver fibrosis: Clinical aspects

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 10-11, 2009, Pages 958-966

  Cales P ^a,b   Boursier, J ^a,b   Chaigneau, J ^a,b   Oberti, F ^a,b   Rousselet, M C ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMILORIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; BAICALEIN; BETA INTERFERON; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GAMMA INTERFERON; GLUCOCORTICOID; HALOFUGINONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; MALOTILATE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PROSTAGLANDIN; RETINOID; ROLIPRAM; S ADENOSYLMETHIONINE; SARTAN DERIVATIVE; SILDENAFIL; SILYMARIN; SPIRONOLACTONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; ZINC;

BASIC RESEARCH; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MONITORING; MORPHOMETRICS; PATIENT COMPLIANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; STAGING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; LIVER FUNCTION TESTS;

EID: 70350622155     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.07.020     Document Type: Short Survey

References (46)

1. Weber S., Gressner O.A., Hall R., Grunhage F., and Lammert F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin Liver Dis 12 (2008) 747-757
2. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
3. Croquet V., Pilette C., Lespine A., Vuillemin E., Rousselet M.C., Oberti F., et al. Hepatic hyper-vitaminosis A: importance of retinyl ester level determination. Eur J Gastroenterol Hepatol 12 (2000) 361-364
4. Watanabe M., Murata S., Hashimoto I., Nakano Y., Ikeda O., Aoyagi Y., et al. Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol 24 (2009) 78-89
5. Witters P., Freson K., Verslype C., Peerlinck K., Hoylaerts M., Nevens F., et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 27 (2008) 1017-1029
6. Lim Y.S., and Kim W.R. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 12 (2008) 733-746
7. Bellentani S., Dalle Grave R., Suppini A., and Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 47 (2008) 746-754
8. Fabrizi F., Bromberg J., Elli A., Dixit V., and Martin P. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment Pharmacol Ther 22 (2005) 657-666
9. Rafiq N., and Younossi Z.M. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2 (2008) 207-215
10. Pinzani M., and Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 12 (2008) 901-913
11. Mallet V., Gilgenkrantz H., Serpaggi J., Verkarre V., Vallet-Pichard A., Fontaine H., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 149 (2008) 399-403
12. Issa R., Zhou X., Constandinou C.M., Fallowfield J., Millward-Sadler H., Gaca M.D., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 (2004) 1795-1808
13. Rousselet M.C., Michalak S., Dupre F., Croue A., Bedossa P., Saint-Andre J.P., et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41 (2005) 257-264
14. Pilette C., Rousselet M.C., Bedossa P., Chappard D., Oberti F., Rifflet H., et al. Histopathological evaluation of liver fibrosis: quantitative image analysis versus semi-quantitative scores. Comparison with serum markers. J Hepatol 28 (1998) 439-446
15. Terui Y., Saito T., Watanabe H., Togashi H., Kawata S., Kamada Y., et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36 (2002) 1022
16. Caballero T., Perez-Milena A., Masseroli M., O'Valle F., Salmeron F.J., Del Moral R.M., et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 34 (2001) 740-747
17. Moal F., Chappard D., Wang J., Vuillemin E., Michalak-Provost S., Rousselet M.C., et al. Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 36 (2002) 840-849
18. Halfon P., Carrat F., Bedossa P., Lambert J., Penaranda G., Perronne C., et al. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02. Antivir Ther 14 (2009) 211-219
19. Vergniol J., Foucher J., Castera L., Bernard P.H., Tournan R., Terrebonne E., et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 16 (2009) 132-140
20. Ichida T., Sugitani S., Satoh T., Matsuda Y., Sugiyama M., Yonekura K., et al. Localization of hyaluronan in human liver sinusoids: a histochemical study using hyaluronan-binding protein. Liver 16 (1996) 365-371
21. Ratti L., Pozzi M., and Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Dig Liver Dis 37 (2005) 886-893
22. Yamagishi S., and Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64 (2005) 476-478
23. Nie L., Imamura M., Itoh H., and Ueno H. Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats. J Uoeh 26 (2004) 165-177
24. Moreno M., and Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 12 (2008) 825-852
25. Pereira R.M., Dos Santos R.A., Teixeira M.M., Leite V.H., Costa L.P., da Costa Dias F.L., et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 46 (2007) 674-681
26. Simoes e Silva A.C., Pinheiro S.V., Pereira R.M., Ferreira A.J., and Santos R.A. The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator. Mini Rev Med Chem 6 (2006) 603-609
27. Croquet V., Moal F., Veal N., Wang J., Oberti F., Roux J., et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 37 (2002) 773-780
28. Sookoian S., Fernandez M.A., and Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 11 (2005) 7560-7563
29. Debernardi-Venon W., Martini S., Biasi F., Vizio B., Termine A., Poli G., et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 46 (2007) 1026-1033
30. Rimola A., Londono M.C., Guevara G., Bruguera M., Navasa M., Forns X., et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78 (2004) 686-691
31. Corey K.E., Shah N., Misdraji J., Abu Dayyeh B.K., Zheng H., Bhan A.K., et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 29 (2009) 748-753
32. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
33. Al Khalaf M.M., Thalib L., and Doi S.A. Cardiovascular outcomes in high-risk patients without heart failure treated with ARB: a systematic review and meta-analysis. Am J Cardiovasc Drugs 9 (2009) 29-43
34. Raimbault M., Veillon H., Oberti F., and Calès P. Médicaments ayant un effet sur la fibrose hépatique. J Afr Hepato Gastroenterol 2 (2008) 1-5
35. Mallat A., Teixeira-Clerc F., Deveaux V., and Lotersztajn S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 11 (2007) 403-409
36. Rombouts K., Kisanga E., Hellemans K., Wielant A., Schuppan D., and Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38 (2003) 564-572
37. Mallat A., Preaux A.M., Blazejewski S., Dhumeaux D., Rosenbaum J., and Mavier P. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 20 (1994) 1589-1594
38. Gardner J.L., Turner S.M., Bautista A., Lindwall G., Awada M., and Hellerstein M.K. Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions. Am J Physiol Gastrointest Liver Physiol 292 (2007) G1695-G1705
39. Thein H.H., Yi Q., Dore G.J., and Krahn M.D. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 22 (2008) 1979-1991
40. Thein H.H., Yi Q., Dore G.J., and Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008) 418-431
41. Gieling R.G., Burt A.D., and Mann D.A. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liver Dis 12 (2008) 915-937
42. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
43. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34 (2001) 730-739
44. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12 (2008) 939-962
45. Calès P., Laine F., Boursier J., Deugnier Y., Moal V., Oberti F., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 50 (2009) 165-173
46. Calès P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381